CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 76 enrolled / 76 target
Drug / intervention
Lansoprazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04248335
NCT04248335Phase 4CompletedOn Track (0.8/mo)Completion was 18mo ago
CompareCT.gov

Physiologic Determinants of PPI Disposition in Children

Children's Mercy Hospital Kansas City·interventional·Posted Jan 30, 2020·Updated Jun 4, 2026

In Brief

A Phase 4 clinical trial evaluating Lansoprazole, Pantoprazole, and 1 other intervention for Pediatric Obesity and 2 related conditions. Completed, enrolled 76 participants across 1 site.

Detailed Summary

This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Obesity, NAFLD, GERD
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJan 30, 2020
Enrollment StartJul 3, 2018
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 6.4 years ago

Arms & Interventions

Children enrolled to receive proton pump inhibitorexperimental

Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam

Drug: LansoprazoleDrug: PantoprazoleDrug: Midazolam

Interventions

Lansoprazoledrug

single-dose administration. Administered to a subset of participants who agreed to receive this drug upon enrollment.

Pantoprazoledrug

single-dose administration. Administered to a subset of participants who agreed to receive this drug upon enrollment.

Midazolamdrug

single-dose administration. Administered to a subset of participants who agreed to receive this drug upon enrollment.